PURPOSE: We sought to evaluate the incidence of vaginal stenosis (VS) and identify clinical and treatment factors that predict for VS in female patients with anal cancer treated with definitive chemoradiation. METHODS AND MATERIALS: The cohort included 95 consecutive women receiving definitive chemoradiation between 2003 and 2012. All but 1 received intensity modulated radiation therapy; median primary tumor dose 50.4 Gy (range, 41.4-60). A modified National Cancer Institute Common Terminology Criteria for Adverse Events version 4 was used to score VS based on the medical record description of dyspareunia, pain with dilator use, vaginal dryness, or difficult pelvic examination. Ordered logistic regression was performed to assess VS predictors. RESULTS: Median age was 60.4 years (range, 19-97). With median follow-up of 2.5 years, 70 women (74%) had adequate information to assess VS. Of these, VS grade distribution was 21.4% grade 0, 14.3% grade 1, 27.1% grade 2, and 37.1% grade 3. By multivariable ordered logistic regression, younger age (P = .02), higher tumor dose (P = .06), and earlier treatment year (P = .04) were associated with higher grade of VS. CONCLUSIONS: VS is a common late complication in women treated definitively with chemoradiation for anal canal cancer. Younger age, higher tumor dose, and earlier year of treatment were associated with a higher grade of stenosis. Prospective investigation into patient reported outcomes is warranted, including sexual function and VS prevention strategies to better understand its effect on long-term survivorship.
PURPOSE: We sought to evaluate the incidence of vaginal stenosis (VS) and identify clinical and treatment factors that predict for VS in female patients with anal cancer treated with definitive chemoradiation. METHODS AND MATERIALS: The cohort included 95 consecutive women receiving definitive chemoradiation between 2003 and 2012. All but 1 received intensity modulated radiation therapy; median primary tumor dose 50.4 Gy (range, 41.4-60). A modified National Cancer Institute Common Terminology Criteria for Adverse Events version 4 was used to score VS based on the medical record description of dyspareunia, pain with dilator use, vaginal dryness, or difficult pelvic examination. Ordered logistic regression was performed to assess VS predictors. RESULTS: Median age was 60.4 years (range, 19-97). With median follow-up of 2.5 years, 70 women (74%) had adequate information to assess VS. Of these, VS grade distribution was 21.4% grade 0, 14.3% grade 1, 27.1% grade 2, and 37.1% grade 3. By multivariable ordered logistic regression, younger age (P = .02), higher tumor dose (P = .06), and earlier treatment year (P = .04) were associated with higher grade of VS. CONCLUSIONS: VS is a common late complication in women treated definitively with chemoradiation for anal canal cancer. Younger age, higher tumor dose, and earlier year of treatment were associated with a higher grade of stenosis. Prospective investigation into patient reported outcomes is warranted, including sexual function and VS prevention strategies to better understand its effect on long-term survivorship.
Authors: Lisa A Kachnic; Kathryn A Winter; Robert J Myerson; Michael D Goodyear; Andre A Abitbol; Oscar E Streeter; Mark E Augspurger; Tracey E Schefter; Alan W Katz; Barbara J Fisher; Lauren E Henke; Samir Narayan; Christopher H Crane Journal: Int J Radiat Oncol Biol Phys Date: 2021-08-14 Impact factor: 8.013
Authors: Scott C Lester; Laura A McGrath; Rachael M Guenzel; Jenae C Quinn; Carolyn J Schultz; T Baron Bradley; Bret D Kazemba; Shima Ito; Christopher L Hallemeier Journal: Int J Part Ther Date: 2022-04-26
Authors: John M Stahl; Jack M Qian; Christopher J Tien; David J Carlson; Zhe Chen; Elena S Ratner; Henry S Park; Shari Damast Journal: Support Care Cancer Date: 2018-09-05 Impact factor: 3.603
Authors: Divya Yerramilli; Lorraine Drapek; Ryan D Nipp; Nora Horick; Samantha M C Moran; Bridget Noé; Sara M D'Arpino; Devarati Mitra; Theodore S Hong; David P Ryan; Don S Dizon; Jennifer Wo Journal: J Gastrointest Cancer Date: 2020-03
Authors: Sabrina Rosa de Lima Matos; Mariana Lucas Rocha Cunha; Sergio Podgaec; Eduardo Weltman; Ana Fernanda Yamazaki Centrone; Ana Carolina Cintra Nunes Mafra Journal: PLoS One Date: 2019-08-09 Impact factor: 3.240
Authors: Hendrik Dapper; Markus Oechsner; Stefan Münch; Christian Diehl; Jan C Peeken; Kai Borm; Stephanie E Combs Journal: Strahlenther Onkol Date: 2020-02-03 Impact factor: 3.621